CommercialCoverageMedium impact
Tildrakizumab-asmn (Ilumya®)
Independence Blue Cross·PA · Dermatology, Rheumatology·Pharmacy
Effective date
Sep 14, 2026
We identified it
Jun 16, 2026
Summary
New policy for Tildrakizumab-asmn (Ilumya®) effective 09/14/2026 adds a requirement that patients cannot receive concurrent therapy with other biologic DMARDs or JAK inhibitors. All ICD-10 codes have been removed from the policy, requiring providers to report the most appropriate diagnosis codes based on medical necessity criteria.
Action Required
By September 14, 2026: Billing team must update prior authorization processes for Tildrakizumab-asmn (Ilumya®) to verify patients are not receiving concurrent biologic DMARD or JAK inhibitor therapy. Update encounter forms and EMR templates to remove specific ICD-10 codes and ensure providers document appropriate diagnosis codes supporting medical necessity. Train staff on new continuation therapy timeframes: 12 weeks for other areas, 16 weeks for scalp, 28 weeks for nail psoriasis.